Anti-Inflammatory Effects of M-MSCs in DNCB-Induced Atopic Dermatitis Mice.
atopic dermatitis (AD)
embryonic stem cell (ESC)
inflammation
mesenchymal stem cell (MSC)
treatment
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
21 Oct 2020
21 Oct 2020
Historique:
received:
09
09
2020
revised:
12
10
2020
accepted:
20
10
2020
entrez:
24
10
2020
pubmed:
25
10
2020
medline:
25
10
2020
Statut:
epublish
Résumé
Atopic dermatitis (AD) is an inflammatory skin disease caused by an imbalance between Th1 and Th2 cells. AD patients suffer from pruritus, excessive dryness, red or inflamed skin, and complications such as sleep disturbances and depression. Although there are currently many AD treatments available there are insufficient data on their long-term stability and comparative effects. Moreover, they have limitations due to various side effects. Multipotent mesenchymal stem cells (M-MSCs) might have potential for next-generation AD therapies. MSCs are capable of immune function regulation and local inflammatory response inhibition. M-MSCs, derived from human embryonic stem cells (hESC), additionally have a stable supply. In L507 antibody array, M-MSCs generally showed similar tendencies to bone marrow-derived mesenchymal stem cells (BM-MSCs), although the immunoregulatory function of M-MSCs seemed to be superior to BM-MSCs. Based on the characteristics of M-MSCs on immunoregulatory functions, we tested a M-MSC conditioned media concentrate (MCMC) in mice with AD lesions on their dorsal skin. MCMC significantly decreased RNA expression levels of inflammatory cytokines in the mouse dorsal skin. It also suppressed serum IgE levels. In addition, significant histopathologic alleviation was identified. In conclusion, secretions of M-MSCs have the potential to effectively improve AD-related inflammatory lesions. M-MSCs showed potential for use in next-generation AD treatment.
Identifiants
pubmed: 33096640
pii: biomedicines8100439
doi: 10.3390/biomedicines8100439
pmc: PMC7589030
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Research Foundation of Korea
ID : 2015-M3A9C7030091
Organisme : National Research Foundation of Korea
ID : 2018R1C1B6007354
Organisme : BK21 plus program
ID : -
Références
J Clin Invest. 2011 Aug;121(8):3206-19
pubmed: 21737876
Malawi Med J. 2012 Sep;24(3):69-71
pubmed: 23638278
Ann Allergy Asthma Immunol. 2018 Sep;121(3):340-347
pubmed: 30025911
Int J Oncol. 2013 May;42(5):1770-7
pubmed: 23525470
Dermatol Ther (Heidelb). 2017 Mar;7(1):1-23
pubmed: 28025775
Eur J Immunol. 2003 Aug;33(8):2168-77
pubmed: 12884291
Nat Rev Immunol. 2012 Apr 25;12(5):383-96
pubmed: 22531326
Mol Med Rep. 2018 Aug;18(2):2097-2109
pubmed: 29916546
J Drugs Dermatol. 2016 Aug 1;15(8):925-9
pubmed: 27537991
Tissue Eng Part C Methods. 2015 Mar;21(3):322-9
pubmed: 25190318
Bioinformatics. 2009 Apr 15;25(8):1091-3
pubmed: 19237447
Int Neurourol J. 2018 Jan;22(Suppl 1):S34-45
pubmed: 29385783
Curr Probl Dermatol. 2011;41:112-124
pubmed: 21576952
Toxicol Appl Pharmacol. 2016 Nov 1;310:51-59
pubmed: 27562088
G Ital Dermatol Venereol. 2016 Aug;151(4):403-11
pubmed: 25658440
Science. 1998 Nov 6;282(5391):1145-7
pubmed: 9804556
J Am Acad Dermatol. 2001 Jan;44(1 Suppl):S1-S12
pubmed: 11145790
Stem Cells Transl Med. 2016 Sep;5(9):1268-76
pubmed: 27388242
Hum Vaccin Immunother. 2014;10(12):3544-51
pubmed: 25483705
J Immunol. 2010 May 1;184(9):4688-95
pubmed: 20304823
Nat Immunol. 2014 Nov;15(11):1009-16
pubmed: 25329189
Cell Transplant. 2016;25(6):1057-72
pubmed: 25853338
Stem Cell Res. 2009 Jul;3(1):39-50
pubmed: 19515621
Indian Dermatol Online J. 2014 Oct;5(4):416-25
pubmed: 25396122
Biotechniques. 2003 Feb;34(2):374-8
pubmed: 12613259
Stem Cells. 2014 Mar;32(3):603-8
pubmed: 24123756
J Exp Med. 1999 Oct 4;190(7):915-22
pubmed: 10510081
Methods Mol Biol. 2016;1366:271-285
pubmed: 26585142
Int Immunopharmacol. 2019 Oct;75:105830
pubmed: 31437788
J Allergy Clin Immunol. 2000 Mar;105(3):399-408
pubmed: 10719286
Ann Nutr Metab. 2015;66 Suppl 1:8-16
pubmed: 25925336
Cytokine. 2015 Sep;75(1):57-61
pubmed: 26088754
Psychol Methods. 2016 Sep;21(3):273-90
pubmed: 27213982
Stem Cells. 2015 Apr;33(4):1254-66
pubmed: 25522163
Cold Spring Harb Perspect Biol. 2017 Jul 5;9(7):
pubmed: 28108485
Oncotarget. 2017 Jan 3;8(1):512-522
pubmed: 27888809
Cell Biosci. 2013 Jan 21;3(1):5
pubmed: 23336752
J Invest Dermatol. 2009 Jan;129(1):31-40
pubmed: 19078986
J Dermatol Sci. 2013 Nov;72(2):149-57
pubmed: 23891346
Proc Jpn Acad Ser B Phys Biol Sci. 2015;91(8):423-39
pubmed: 26460320
J Clin Nurs. 1999 Nov;8(6):763
pubmed: 10827624
Cochrane Database Syst Rev. 2015 Jul 01;(7):CD009864
pubmed: 26132597
Int J Stem Cells. 2011 Jun;4(1):24-34
pubmed: 24298331
JAMA Dermatol. 2017 Oct 1;153(10):1036-1042
pubmed: 28724128
Mucosal Immunol. 2011 Nov;4(6):603-11
pubmed: 21975936
J Immunol. 2002 Oct 15;169(8):4417-22
pubmed: 12370375